The Latest Analyst Ratings for Fate Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Fate Therapeutics (NASDAQ:FATE) within the last quarter, with 1 bullish, 1 somewhat bullish, and 3 indifferent ratings. The average 12-month price target for the company is $6.68, representing a 22.95% decrease from the previous average price target of $8.67.
August 16, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mixed analyst ratings and a lower average price target could lead to uncertainty among investors, potentially impacting Fate Therapeutics' stock price in the short term.
Analyst ratings can significantly influence investor sentiment. The mixed ratings for Fate Therapeutics, coupled with a lower average price target, could create uncertainty among investors. This uncertainty may lead to increased volatility in the stock's price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100